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Editorial for effect of dornase alfa on inﬂammation and lung function:
Potential role in the early treatment of cystic ﬁbrosisTreat or lose?
The review by Konstan and Ratjen in this issue of the
Journal of CF underlines the importance of early treatment of
CF lung disease using dornase alfa [1]. Dornase alfa has been
important as mucolytic therapy for CF lung disease since the
mid-nineties. Dornase alfa was the first drug developed specif-
ically for the treatment of CF patients [2]. The dornase alfa
development program included the two-year randomized con-
trolled Pulmozyme Early Intervention Trial (PEIT) [3]. The
PEIT included patients with well-preserved lung function
(Forced Vital CapacityN85%). In the dornase alfa group lung
function was maintained over the two-year study period. As
reviewed by Konstan and Ratjen a large body of evidence on
the efficacy of dornase alfa and its potential mechanisms has
been added to the pivotal studies. Based on this evidence dor-
nase alfa has been recommended in guidelines as a standard
of treatment for children 6 years and above with mild to severe
lung disease. Despite these recommendations a large number of
young patients with high lung function but without dornase alfa
treatment could be found in the database of the Epidemiologic
Study of CF (ESCF). In an analysis of the ESCF database by
Konstan elevated risk of immediate rapid decline in these
untreated patients was shown underscoring the need for early
and aggressive treatment to preserve lung function. Why is it
that, despite all the evidence on dornase alfa in early disease,
its implementation is incomplete? Some patients are probably
considered too good to benefit from the treatment by their clini-
cians. This reminds me of a discussion I had 15 years ago with
one of the inventors of dornase alfa. We discussed the results of
the PEIT study and he challenged me on my conclusion that I
was reluctant to start dornase alfa treatment in CF patients
with normal lung function. ‘So you want patients with well-
preserved lung function to lose function’ he argued. He was
right, the PEIT data showed us that we should aim for preserva-
tion of ‘healthy’ lungs and not only focus on the obviously sick
lungs. It is now well recognized that normal spirometry does
not exclude chronic lower airway inflammation, infection, and
structural damage.1569-1993/$ -see front matter © 2012 Published by Elsevier B.V. on behalf of Eur
doi:10.1016/j.jcf.2012.03.001Unfortunately, large randomized controlled trials like the
PEIT have major limitations. It does not help us to determine
whether a patient sitting in front of us in our outpatient clinic
will be a responder or non-responder. It only teaches us that pa-
tients who met the PEIT inclusion criteria and who were ran-
domized to dornase alfa had on average no loss of FEV1 over
a 2-year study period in contrast to the placebo treated patients.
Hence, evidence-based medicine defines for us what works for
a group of patients that meet certain inclusion characteristics.
Until we have developed reliable prediction models that allow
us to predict outcome from an intervention for an individual
based on key characteristics we are stuck to ‘one size fits all’.
Hence, as advocated by Konstan and Ratjen in their review
there is ‘a greater role for dornase alfa therapy in the early treat-
ment of CF, where it may help preserve lung function and
potentially extend survival’.References
[1] Konstan MW, Ratjen F. Effect of dornase alfa on inflammation and lung
function: potential role in the early treatment of cystic fibrosis. J Cyst
Fibros 2012 e-pub 2011/11/19.
[2] Bakker EM, Tiddens HA. Phamacology, clinical efficacy and safety of re-
combinant human DNase in cystic fibrosis. Expert Rev Resp Med
2007;1(3):317–29.
[3] Quan JM, Tiddens HA, et al. A two-year randomized, placebo controlled
trial of dornase alfa in young cystic fibrosis patients with mild lung function
abnormalities. J Pediatr 2001;139:813–20.Harm A.W.M. Tiddens
Department of Pediatric Pulmonology and Allergology,
Erasmus Medical Center-Sophia Children's Hospital,
The Netherlands
Department of Radiology, Erasmus Medical Center-Sophia
Children's Hospital, The Netherlands
Dr. Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands.
Tel.: +31 10 7036263; fax: +31 10 7036800.
E-mail address: h.tiddens@erasmusmc.nl.opean Cystic Fibrosis Society.
